Registry Study on Drug Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBeijing Anzhen Hospital
About this trial
Registry Study on Drug Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Informed consent has been signed.
Patients diagnosed in our hospital with acute coronary syndrome.
Age ≥18.
Life expectancy ≥12 months.
Disqualifiers
Severe lack of important information such as history of previous medication, history of previous disease, history of surgery.
Pregnant and lactating women.
Mental disorders, or inability to communicate effectively with researchers, or failure to comply with research protocols.
Trial population
Patients with Acute Coronary Syndrome with blood concentration monitoring or genetic testing at the pharmacy department of Beijing Anzhen Hospital from January 1, 2018.Those who fill the inclusion criteria at screening will be invited for the registry study into different groups.
Trial design
Design model
Other
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
main adverse cardiovascular and cerebrovascular events (MACCE)
MACCE will be defined as all-cause death, non-fatal stroke, non-fatal myocardial infarction (MI), and ischemic-driven revascularization.
Time frame
up to 5 yearsSecondary outcomes
1
Adverse drug reaction
Adverse drug reaction will be defined as any adverse reactions in the patients.
Time frame
up to 5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: